$Quantum BioPharma (QNTM.US)$
Quantum BioPharma Advances in Lucid-21-302 clinical Trial
Quantum BioPharma’s safety review committee has recommended moving forward with dosing the second cohort in its Phase 1 clinical trial for Lucid-21-302, targeting multiple sclerosis. This decision comes after positive safety evaluations from the first cohort, marking a significant step in the company’s innovative drug development efforts.

$Quantum BioPharma (QNTM.US)$
Quantum Biopharma Announces Closing of Second Tranche
Friday, 20th December at 7:30 pm
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ: QNTM)(CSE: QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it has closed a second tranche ("Second Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") and has issued 500 Debenture Units (as defined in the December 5 NR) for $500,000.
The C...